SIRT3 and non-small cell lung carcinoma: SIRT3 hinders EMT by activating AMPK and inhibiting mTOR/HIF-1α pathway, which further inhibits cancer-associated fibroblast-mediated tumorigenesis in non-small cell lung cancer (NSCLC) 76.